30.08.2023 15:15:06 - dpa-AFX: GNW-Adhoc: Renovaro BioSciences Welcomes GEDiCube Announcement of New Joint Effort
LOS ANGELES, Aug. 30, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RENB). Renovaro
BioSciences congratulates GEDiCube on their joint effort to work to accelerate
early diagnosis of cancer in clinical trials.
For more information: GEDiCube Press Release
(https://www.businesswire.com/news/home/20230830575428/en/GEDiCube-Joins-NVIDIA-
Inception-to-Advance-Unique-Platform-for-Early-Cancer-Detection-in-Clinical-
Trials)
FORWARD-LOOKING STATEMENT
Statements in this press release that are not strictly historical in nature are
forward-looking statements. These statements are only predictions based on
current information and expectations and involve a number of risks and
uncertainties, including but not limited to the success or efficacy of our
pipeline. All statements other than historical facts are forward-looking
statements, which can be identified by the use of forward-looking terminology
such as "believes," "plans," "expects," "aims," "intends," "potential," or
similar expressions. All forward-looking statements are based on assumptions or
judgments about future events and economic conditions that may or may not be
correct or necessarily take place and that are by their nature, subject to
significant risks, uncertainties, and contingencies. These forward-looking
statements include but are not limited to, statements regarding the Renovaro-
GEDi Cube transaction and Renovaro's plans and expectations with respect to the
potential transaction. Actual events or results may differ materially from those
projected in any of such statements due to various uncertainties, including as
set forth in Renovaro BioSciences Inc. (NASDAQ: RENB) most recent Annual Report
on Form 10-K filed with the SEC as well as whether Renovaro and GEDi Cube will
enter into an agreement as to the definitive terms of the transaction; a
condition to consummating the transaction may not be satisfied; Renovaro may be
unable to obtain approval to list on the Nasdaq Capital Market the shares of
Renovaro common stock expected to be issued pursuant to the transaction; the
closing of the transaction might be delayed or not occur at all. Readers are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. All forward-looking statements are qualified
in their entirety by this cautionary statement, and Renovaro Biosciences, Inc.
undertakes no obligation to revise or update this shareholder letter to reflect
events or circumstances after the date hereof.
Â